Soleno Therapeutics Investor Relations Material

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of rare diseases. The company's primary focus is on Prader-Willi Syndrome (PWS), a genetic disorder characterized by chronic hunger, behavioral problems, and other severe health issues. Soleno's lead product candidate, Diazoxide Choline Extended-Release (DCCR) tablets, is currently undergoing evaluation in a Phase III clinical trial as a potential treatment for PWS. This once-daily oral medication aims to address the disorder's hallmark symptoms and improve patient outcomes. The company is headquartered in Redwood City, California, and its shares are listed on NASDAQ.